To compare the efficacy and safety of gefitinib combined with bevacizumab and gefitinib in the treatment of L858R positive mutation in exon 21 of EGFR gene in advanced NSCLC.
Name: Gefitinib
Name: Bevacizumab Combined With Gefitinib
Description: The PFS of gefitinib combined with bevacizumab and gefitinib alone were compared in patients with L858R mutation in exon 21 of EGFR gene in stage IIIB-IV local advanced, recurrent or metastatic NSCLC.
Measure: Progression-free survival (PFS) Time: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 18 monthsAllocation: Randomized
Parallel Assignment
There is one SNP
Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC Clinical Study of L858R Positive Mutation Patients. --- L858R ---
Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC To compare the efficacy and safety of gefitinib combined with bevacizumab and gefitinib in the treatment of L858R positive mutation in exon 21 of EGFR gene in advanced NSCLC. --- L858R ---
The PFS of gefitinib combined with bevacizumab and gefitinib alone were compared in patients with L858R mutation in exon 21 of EGFR gene in stage IIIB-IV local advanced, recurrent or metastatic NSCLC.. Inclusion Criteria: 1. Age ≥ 18 years old, gender unlimited. --- L858R ---
4. According to the method of second-generation sequencing, L858R point mutation in exon 21 of EGFR gene was found in primary NSCLC with or without any other coexisting mutations. --- L858R ---